Effectiveness and safety of surufatinib in treating pheochromocytomas and paragangliomas

#4122

Introduction: Pheochromocytomas and paragangliomas (PPGLs), classified as malignant by WHO in 2017, are partly catecholamine-secreting neuroendocrine tumors (NET). The 5-year overall survival rate of metastases PPGLs (mPPGL) is only between 50% and 60%. Surufatinib, approved for the treatment of NET, with anti-angiogenic and immunomodulatory properties, offers potential as a potential candidate for treating mPPGL.

Aim(s): This study assesses the therapeutic efficacy and safety of surufatinib in patients with PPGLs.

Materials and methods: Adult mPPGL patients with measurable lesions (RECIST 1.1) and ECOG status 0-3 were enrolled. Surufatinib at 300 mg daily was administered, and radiographic evaluations were conducted bi-monthly. The study's primary endpoint was median progression-free survival (mPFS), with secondary endpoints including objective response rate (ORR), disease control rate (DCR), and safety.

Conference:

Presenting Author:

Authors: Su T, Zhong X, Song Q, Wang W,

Keywords: Pheochromocytomas and paragangliomas, treatment, Surufatinib,